Drug Combination Details
| General Information of the Combination (ID: C03914) | |||||
|---|---|---|---|---|---|
| Name | Astilbin NP Info | + | Methotrexate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Rheumatoid arthritis
[ICD-11: FA20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | STAT1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Specific-pathogen-free, eight-week-old male DBA/1J mice, and Eight-week-old C57BL/6 mice were used in this study. | |||||
| Experimental
Result(s) |
Astilbin is a valuable candidate for low-dose MTX combined therapy in RA via increasing A2AAR/adenosine system and decreasing ERK/NFKappaB/STATs signals. | |||||
